Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia
Status:
Terminated
Trial end date:
2018-07-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well pioglitazone hydrochloride and tyrosine kinase inhibitor
(TKI) therapy works in treating patients with chronic myeloid leukemia (CML) that has come
back after a period of improvement (relapsed) after a first TKI discontinuation. TKI may stop
the growth of cancer cells by blocking certain enzymes need for cell growth. Although TKI
therapies are effective against CML, there are residual cancer cells called leukemia stem
cells that are able to hide from TKIs. Pioglitazone is a drug approved by the Food and Drug
Administration to treat diabetes and has been shown in laboratory studies to increase CML
stem cell death when given together with TKI therapy. Giving pioglitazone with TKI therapy
may be effective in treating patients with CML.